These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 22860188)
1. A simple method for quantifying functional selectivity and agonist bias. Kenakin T; Watson C; Muniz-Medina V; Christopoulos A; Novick S ACS Chem Neurosci; 2012 Mar; 3(3):193-203. PubMed ID: 22860188 [TBL] [Abstract][Full Text] [Related]
2. A Complementary Scale of Biased Agonism for Agonists with Differing Maximal Responses. Burgueño J; Pujol M; Monroy X; Roche D; Varela MJ; Merlos M; Giraldo J Sci Rep; 2017 Nov; 7(1):15389. PubMed ID: 29133887 [TBL] [Abstract][Full Text] [Related]
3. A method for the quantification of biased signalling at constitutively active receptors. Hall DA; Giraldo J Br J Pharmacol; 2018 Jun; 175(11):2046-2062. PubMed ID: 29498414 [TBL] [Abstract][Full Text] [Related]
4. Muscarinic and antimuscarinic activity of acetamides related to oxotremorine in the guinea pig urinary bladder. Ringdahl B; Markowicz ME J Pharmacol Exp Ther; 1987 Mar; 240(3):789-94. PubMed ID: 3559974 [TBL] [Abstract][Full Text] [Related]
5. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors. Loudon JM; Bromidge SM; Brown F; Clark MS; Hatcher JP; Hawkins J; Riley GJ; Noy G; Orlek BS J Pharmacol Exp Ther; 1997 Dec; 283(3):1059-68. PubMed ID: 9399977 [TBL] [Abstract][Full Text] [Related]
7. Analysis of functional selectivity through G protein-dependent and -independent signaling pathways at the adrenergic α(2C) receptor. Kurko D; Kapui Z; Nagy J; Lendvai B; Kolok S Brain Res Bull; 2014 Aug; 107():89-101. PubMed ID: 25080296 [TBL] [Abstract][Full Text] [Related]
8. Unravelling intrinsic efficacy and ligand bias at G protein coupled receptors: A practical guide to assessing functional data. Stott LA; Hall DA; Holliday ND Biochem Pharmacol; 2016 Feb; 101():1-12. PubMed ID: 26478533 [TBL] [Abstract][Full Text] [Related]
9. Regulation of muscarinic cationic current in myocytes from guinea-pig ileum by intracellular Ca2+ release: a central role of inositol 1,4,5-trisphosphate receptors. Gordienko DV; Zholos AV Cell Calcium; 2004 Nov; 36(5):367-86. PubMed ID: 15451621 [TBL] [Abstract][Full Text] [Related]
10. Being mindful of seven-transmembrane receptor 'guests' when assessing agonist selectivity. Kenakin T Br J Pharmacol; 2010 Jul; 160(5):1045-7. PubMed ID: 20590598 [TBL] [Abstract][Full Text] [Related]
12. Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect. Kenakin T ACS Chem Biol; 2009 Apr; 4(4):249-60. PubMed ID: 19193052 [TBL] [Abstract][Full Text] [Related]
13. Quantification of adenosine A(1) receptor biased agonism: Implications for drug discovery. Baltos JA; Gregory KJ; White PJ; Sexton PM; Christopoulos A; May LT Biochem Pharmacol; 2016 Jan; 99():101-12. PubMed ID: 26581123 [TBL] [Abstract][Full Text] [Related]
14. Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15. Griffin MT; Figueroa KW; Liller S; Ehlert FJ J Pharmacol Exp Ther; 2007 Jun; 321(3):1193-207. PubMed ID: 17392404 [TBL] [Abstract][Full Text] [Related]
15. Quantification of functional selectivity at the human α(1A)-adrenoceptor. Evans BA; Broxton N; Merlin J; Sato M; Hutchinson DS; Christopoulos A; Summers RJ Mol Pharmacol; 2011 Feb; 79(2):298-307. PubMed ID: 20978120 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological basis for functional selectivity of partial muscarinic receptor agonists. Heldman E; Barg J; Fisher A; Levy R; Pittel Z; Zimlichman R; Kushnir M; Vogel Z Eur J Pharmacol; 1996 Feb; 297(3):283-91. PubMed ID: 8666061 [TBL] [Abstract][Full Text] [Related]
17. The endomorphin-1/2 and dynorphin-B peptides display biased agonism at the mu opioid receptor. LaVigne J; Keresztes A; Chiem D; Streicher JM Pharmacol Rep; 2020 Apr; 72(2):465-471. PubMed ID: 32112361 [TBL] [Abstract][Full Text] [Related]
18. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Beattie DT; Cheruvu M; Mai N; O'Keefe M; Johnson-Rabidoux S; Peterson C; Kaufman E; Vickery R Naunyn Schmiedebergs Arch Pharmacol; 2007 May; 375(3):205-20. PubMed ID: 17340127 [TBL] [Abstract][Full Text] [Related]
19. Quantifying agonist activity at G protein-coupled receptors. Ehlert FJ; Suga H; Griffin MT J Vis Exp; 2011 Dec; (58):e3179. PubMed ID: 22231636 [TBL] [Abstract][Full Text] [Related]
20. Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased μ opioid receptor agonists. Winpenny D; Clark M; Cawkill D Br J Pharmacol; 2016 Apr; 173(8):1393-403. PubMed ID: 26791140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]